TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial
Brief Summary: 200 women with PPH will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) and group 2 will receive oxytocin 10 IU (Syntocinon®, Novartis, Switzerland). The investigators will not include a control group for ethical reasons.


Options:
A: Arm Label: 15-methyl prostaglandin F2α; Type: ACTIVE_COMPARATOR; Interventions: Drug: 15-methyl prostaglandin F2α, Drug: Methylergonovine Maleate | Arm Label: Methylergonovine Maleate; Type: ACTIVE_COMPARATOR; Interventions: Drug: 15-methyl prostaglandin F2α, Drug: Methylergonovine Maleate | Intervention Type: DRUG; Name: 15-methyl prostaglandin F2α; Assigned to Arm(s): 15-methyl prostaglandin F2α, Methylergonovine Maleate | Intervention Type: DRUG; Name: Methylergonovine Maleate; Assigned to Arm(s): 15-methyl prostaglandin F2α, Methylergonovine Maleate
B: Arm Label: oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxytocin | Arm Label: oxytocin plus misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxytocin, Drug: oxytocin plus misoprostol | Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: oxytocin; Assigned to Arm(s): oxytocin, oxytocin plus misoprostol | Intervention Type: DRUG; Name: oxytocin plus misoprostol; Assigned to Arm(s): oxytocin plus misoprostol | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin
C: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Other: Misoprostol + referral | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo + referral | Intervention Type: OTHER; Name: Misoprostol + referral; Assigned to Arm(s): Misoprostol | Intervention Type: OTHER; Name: Placebo + referral; Assigned to Arm(s): Placebo
D: Arm Label: Ergometrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ergometrine | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Ergometrine; Assigned to Arm(s): Ergometrine | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Augmented Versus Routine Approach to Giving Energy Trial: A Randomised Controlled Trial
Brief Summary: Nutrition therapy is an essential standard of care for all critically ill patients who are mechanically ventilated and remain in the intensive care unit for more than a few days.

The investigators plan to conduct a 4,000 patient, double-blind, randomised controlled trial to determine if augmentation of calorie delivery using energy dense enteral nutrition in mechanically ventilated patients improves 90 day survival when compared to routine care.


Options:
A: Arm Label: Early enteral nutrition; Type: EXPERIMENTAL; Interventions: Drug: early enteral nutrition | Arm Label: Delayed enteral nutrition; Type: ACTIVE_COMPARATOR; Interventions: Drug: Delayed enteral nutrition | Intervention Type: DRUG; Name: early enteral nutrition; Assigned to Arm(s): Early enteral nutrition | Intervention Type: DRUG; Name: Delayed enteral nutrition; Assigned to Arm(s): Delayed enteral nutrition
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding, Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Full Feeding, Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding, Dietary Supplement: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Full Feeding, Dietary Supplement: Placebo | Intervention Type: BEHAVIORAL; Name: Minimal (Trophic) Feeding; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: Full Feeding; Assigned to Arm(s): 2, 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acids and Antioxidant Supplements; Assigned to Arm(s): 1, 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3, 4
C: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
D: Arm Label: TARGET protocol EN 1.5 kcal/mL; Type: EXPERIMENTAL; Interventions: Dietary Supplement: TARGET protocol EN 1.5 kcal/mL | Arm Label: TARGET protocol EN 1.0 kcal/mL; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: TARGET protocol EN 1.0 kcal/mL | Intervention Type: DIETARY_SUPPLEMENT; Name: TARGET protocol EN 1.5 kcal/mL; Assigned to Arm(s): TARGET protocol EN 1.5 kcal/mL | Intervention Type: DIETARY_SUPPLEMENT; Name: TARGET protocol EN 1.0 kcal/mL; Assigned to Arm(s): TARGET protocol EN 1.0 kcal/mL

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Smoking Reduction on Endothelial Glucocalyx and Arterial Wall Properites During Medically-aided Smoking Cessation Program.
Brief Summary: The integrity of endothelial glucocalyx plays a vital role in vascular permeability and inflammation. Smoking cessation is related with improved vascular function and is a key component of secondary cardiovascular prevention. Pharmacotherapy is a standard component of evidence based smoking cessation treatment. This study was designed to determine the effects medically-aided smoking cessation on glucocalyx thickness and arterial elasticity smoking cessation programs


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): nicotine
C: Arm Label: Randomized Phase: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Randomized Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Randomized Phase: Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Phase: Placebo
D: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Receiving Treatment for More Than 8 Hours Before Delivery. A Randomized Multicenter Clinical Trial .
Brief Summary: There is no evidence that patients receiving magnesium sulfate before birth are required to maintain the drug for 24 hours. Therefore the investigators will have a randomized clinical study in patients with severe preeclampsia who have been treated with impregnation of magnesium sulphate and at least eight hours have received the drug before birth. If the patient agrees and signs the consent is randomized to: 1-receive sulfate for 24 hours postpartum as usual or, 2- not receiving the postpartum magnesium sulfate or other anticonvulsant drugs. This study can be conducted in 12 maternity latin america.


Options:
A: Arm Label: Six Hours Postpartum; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulfate | Arm Label: Twenty-four hours Postpartum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium Sulfate | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): Six Hours Postpartum, Twenty-four hours Postpartum
B: Arm Label: MgSO4 4g load, 1g/hr infusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium sulfate 4g loading dose, 1g/hr infusion | Arm Label: MgSO4 6g load, 2g/hr infusion; Type: EXPERIMENTAL; Interventions: Drug: Magnesium sulfate 6g loading dose, 2g/hr infusion | Intervention Type: DRUG; Name: Magnesium sulfate 4g loading dose, 1g/hr infusion; Assigned to Arm(s): MgSO4 4g load, 1g/hr infusion | Intervention Type: DRUG; Name: Magnesium sulfate 6g loading dose, 2g/hr infusion; Assigned to Arm(s): MgSO4 6g load, 2g/hr infusion
C: Arm Label: IV; Type: ACTIVE_COMPARATOR; Interventions: Other: IV administration, Drug: Magnesium Sulfate | Arm Label: Springfusor; Type: EXPERIMENTAL; Interventions: Device: Springfusor infusion pump, Drug: Magnesium Sulfate | Intervention Type: DEVICE; Name: Springfusor infusion pump; Assigned to Arm(s): Springfusor | Intervention Type: OTHER; Name: IV administration; Assigned to Arm(s): IV | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): IV, Springfusor
D: Arm Label: Postpartum Magnesium sulfate; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulfate | Arm Label: No postpartum treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): Postpartum Magnesium sulfate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Two Human Milk Fortifiers in Preterm Infants
Brief Summary: The purpose of this study is to assess growth of preterm infants fed human milk supplemented with one of two commercially available human milk fortifiers.


Options:
A: Arm Label: Individualized fortification of breast milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Individualized fortification of breast milk | Arm Label: Routine fortification of breast milk; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Routine fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Individualized fortification of breast milk; Assigned to Arm(s): Individualized fortification of breast milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Routine fortification of breast milk; Assigned to Arm(s): Routine fortification of breast milk
B: Arm Label: Study Human Milk Fortifier A; Type: ACTIVE_COMPARATOR; Interventions: Other: Human Milk Fortifier A | Arm Label: Study Human Milk Fortifier B; Type: EXPERIMENTAL; Interventions: Other: Human Milk Fortifier B | Intervention Type: OTHER; Name: Human Milk Fortifier A; Assigned to Arm(s): Study Human Milk Fortifier A | Intervention Type: OTHER; Name: Human Milk Fortifier B; Assigned to Arm(s): Study Human Milk Fortifier B
C: Arm Label: Standard Protein Group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard fortification | Arm Label: Enhanced Protein Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein supplementation, Dietary Supplement: Standard fortification | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein supplementation; Assigned to Arm(s): Enhanced Protein Group | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard fortification; Assigned to Arm(s): Enhanced Protein Group, Standard Protein Group
D: Arm Label: High Dose Protein (Individualized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Individualized) | Arm Label: High Dose Protein (Standardized); Type: EXPERIMENTAL; Interventions: Dietary Supplement: High Dose Protein (Standardized) | Arm Label: Standard protein supplementation; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard Protein Supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Individualized); Assigned to Arm(s): High Dose Protein (Individualized) | Intervention Type: DIETARY_SUPPLEMENT; Name: High Dose Protein (Standardized); Assigned to Arm(s): High Dose Protein (Standardized) | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard Protein Supplementation; Assigned to Arm(s): Standard protein supplementation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bakery Products for Non-Coeliac Gluten Sensitive Consumers
Brief Summary: The aim of the study is to produce a tolerable alternative to normal wheat bread which would be suitable for subjects with self-reported non-coeliac gluten sensitivity (NCGS). The bread would be made from wheat so, in contrast to gluten-free bread, would be more comparable to standard bread. To make this bread, the investigators will use advanced enzyme technology and/or novel formulations to target the digestion or removal of wheat proteins, which might be involved in the etiology of non-coeliac gluten sensitivity, preferentially over other those that are more useful for baking quality. The investigators will determine palatability and tolerance of this new product in a human cross-over, randomised, blind and placebo-controlled intervention study.

It has been estimated 6-10% of the population are sensitive to gluten who do not have coeliac disease (CD). Three breads will be produced and tested in this study against a suitable reference based on standard wheat flour and baking process


Options:
A: Arm Label: gluten-containing diet; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Active comparator, gluten-free diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Gluten-free diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Gluten-free diet; Assigned to Arm(s): Active comparator, gluten-free diet
B: Arm Label: Gluten-free diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Gluten-free diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Gluten-free diet; Assigned to Arm(s): Gluten-free diet
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Other: Normal gluten containing bread | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Other: Bread with reduced gliadins content | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Other: Bread with reduced ATIs content | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Other: Bread with reduced overall protein content | Intervention Type: OTHER; Name: Normal gluten containing bread; Assigned to Arm(s): Group 1 | Intervention Type: OTHER; Name: Bread with reduced gliadins content; Assigned to Arm(s): Group 2 | Intervention Type: OTHER; Name: Bread with reduced ATIs content; Assigned to Arm(s): Group 3 | Intervention Type: OTHER; Name: Bread with reduced overall protein content; Assigned to Arm(s): Group 4
D: Arm Label: patients with IBS treated with gluten; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: diet containing gluten | Arm Label: patients with IBS treated with placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Diet containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: diet containing gluten; Assigned to Arm(s): patients with IBS treated with gluten | Intervention Type: DIETARY_SUPPLEMENT; Name: Diet containing placebo; Assigned to Arm(s): patients with IBS treated with placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient Decision Aid (PDA) for Antidepressant Use In Pregnancy
Brief Summary: The purpose of this pilot study is to examine the feasibility of conducting a multi-site randomized controlled trial whose aim will be to evaluate the effectiveness of a Patient Decision Aid (PDA) for antidepressant use in pregnancy.


Options:
A: Arm Label: Patient Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: Patient Decision Aid | Arm Label: Record-only control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Patient Decision Aid; Assigned to Arm(s): Patient Decision Aid
B: Arm Label: Standard Resource Sheet; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard Resource Sheet | Arm Label: Electronic Patient Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Electronic Patient Decision Aid, Behavioral: Standard Resource Sheet | Intervention Type: BEHAVIORAL; Name: Electronic Patient Decision Aid; Assigned to Arm(s): Electronic Patient Decision Aid | Intervention Type: BEHAVIORAL; Name: Standard Resource Sheet; Assigned to Arm(s): Electronic Patient Decision Aid, Standard Resource Sheet
C: Arm Label: Implementation Facilitation; Type: EXPERIMENTAL; Interventions: Other: Replicating Effective Programs plus External Facilitation | Arm Label: Educational Materials; Type: PLACEBO_COMPARATOR; Interventions: Other: Educational Materials | Intervention Type: OTHER; Name: Replicating Effective Programs plus External Facilitation; Assigned to Arm(s): Implementation Facilitation | Intervention Type: OTHER; Name: Educational Materials; Assigned to Arm(s): Educational Materials
D: Arm Label: Using Power Up; Type: EXPERIMENTAL; Interventions: Behavioral: Shared Decision Making tool | Arm Label: Not using Power Up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shared Decision Making tool; Assigned to Arm(s): Using Power Up

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Noninvasive brain stimulations (NIBS) will be used in healthy volunteers and in chronic stroke patients to improve bimanual activities and motor learning.

Functional magnetic resonance imaging will be used to evaluate the mechanisms underlying bimanual activities and motor learning in healthy volunteers and in chronic stroke patients.

A neuro-rehabilitation robot (REA2PLAN, AXINESIS, Louvain-la-Neuve, Belgium) will be used for motor learning.


Options:
A: Arm Label: High Intensity; Type: EXPERIMENTAL; Interventions: Behavioral: Bilateral movements and neuromuscular electrical stimulation | Arm Label: Low Intensity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bilateral movements and neuromuscular electrical stimulation | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bilateral movements and sham electrical stimulation | Intervention Type: BEHAVIORAL; Name: Bilateral movements and neuromuscular electrical stimulation; Assigned to Arm(s): High Intensity | Intervention Type: BEHAVIORAL; Name: Bilateral movements and neuromuscular electrical stimulation; Assigned to Arm(s): Low Intensity | Intervention Type: BEHAVIORAL; Name: Bilateral movements and sham electrical stimulation; Assigned to Arm(s): Control
B: Arm Label: real tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: tDCS | Arm Label: Sham tDCS; Type: PLACEBO_COMPARATOR; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): Sham tDCS, real tDCS
C: Arm Label: real tDCS + TOCT; Type: EXPERIMENTAL; Interventions: Device: real tDCS + TOCT | Arm Label: sham tDCS + TOCT; Type: ACTIVE_COMPARATOR; Interventions: Device: sham tDCS + TOCT | Intervention Type: DEVICE; Name: sham tDCS + TOCT; Assigned to Arm(s): sham tDCS + TOCT | Intervention Type: DEVICE; Name: real tDCS + TOCT; Assigned to Arm(s): real tDCS + TOCT
D: Arm Label: Sham tDCS and motor training: sham comparator; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Arm Label: Anodal tDCS and motor training: experimental; Type: EXPERIMENTAL; Interventions: Device: anodal tDCS (device) Eldith DC-Stimulator | Intervention Type: DEVICE; Name: anodal tDCS (device) Eldith DC-Stimulator; Assigned to Arm(s): Anodal tDCS and motor training: experimental | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham tDCS and motor training: sham comparator

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Noninvasive brain stimulations (NIBS) will be used in healthy volunteers and in chronic stroke patients to improve bimanual activities and motor learning.

Functional magnetic resonance imaging will be used to evaluate the mechanisms underlying bimanual activities and motor learning in healthy volunteers and in chronic stroke patients.

A neuro-rehabilitation robot (REA2PLAN, AXINESIS, Louvain-la-Neuve, Belgium) will be used for motor learning.


Options:
A: Arm Label: real tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: tDCS | Arm Label: Sham tDCS; Type: PLACEBO_COMPARATOR; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): Sham tDCS, real tDCS
B: Arm Label: Action Training; Type: ACTIVE_COMPARATOR; Interventions: Other: Action Training | Arm Label: tDCS; Type: EXPERIMENTAL; Interventions: Other: Transcranial direct current stimulation | Arm Label: Action Training + tDCs; Type: EXPERIMENTAL; Interventions: Other: Transcranial direct current stimulation, Other: Action Training | Arm Label: Control training; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: OTHER; Name: Transcranial direct current stimulation; Assigned to Arm(s): Action Training + tDCs, tDCS | Intervention Type: OTHER; Name: Action Training; Assigned to Arm(s): Action Training, Action Training + tDCs
C: Arm Label: RBX + tDCS; Type: EXPERIMENTAL; Interventions: Drug: reboxetine, Device: tDCS verum | Arm Label: RBX + sham stimulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: reboxetine, Device: tDCS sham | Arm Label: PLC + tDCS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Device: tDCS verum | Arm Label: PLC + sham stimulation; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo, Device: tDCS sham | Intervention Type: DRUG; Name: reboxetine; Assigned to Arm(s): RBX + sham stimulation, RBX + tDCS | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLC + sham stimulation, PLC + tDCS | Intervention Type: DEVICE; Name: tDCS verum; Assigned to Arm(s): PLC + tDCS, RBX + tDCS | Intervention Type: DEVICE; Name: tDCS sham; Assigned to Arm(s): PLC + sham stimulation, RBX + sham stimulation
D: Arm Label: Upper limb motor function training + tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: transcranial direct current stimulation (tDCS) | Arm Label: upper limb motor function training + sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: transcranial direct current stimulation (tDCS) | Intervention Type: DEVICE; Name: transcranial direct current stimulation (tDCS); Assigned to Arm(s): Upper limb motor function training + tDCS, upper limb motor function training + sham tDCS

Answer: A